Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07472517 · ClinicalTrials.gov registry record · Phase 3
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 670
- Enrollment target
NCT07472517 is a Phase 3 study that is actively recruiting participants, run by Boehringer Ingelheim. The registered enrollment target is 670 participants.
The verdict
NCT07472517, a Phase 3 study, is actively recruiting participants, sponsored by Boehringer Ingelheim.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 670 participants
- Enrollment target
Study Summary
This study is open to adults with advanced small cell lung cancer (SCLC). The purpose of this study is to find out if a study medicine called obrixtamig plus standard treatment (atezolizumab, carboplatin, and etoposide) improves survival when compared to standard treatment alone. Obrixtamig is an antibody-like molecule that may help the immune system fight cancer. Another purpose of the study is to test a medical device being developed to measure levels of the tumour marker DLL3. Participants are put into 2 groups randomly, which means by chance. One group receives obrixtamig and standard treatment. The other group receives standard treatment without obrixtamig. All treatments are given as infusions into a vein. Participants are in the study for up to 3 years. During this time, they visit the study site regularly. Participants in the group receiving obrixtamig stay overnight at the study site following the first 2 obrixtamig treatments. At the visits, doctors check the size of the tumour(s). The results are compared between the 2 groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.
Interventions
- DRUG carboplatin
- DRUG etoposide
- DRUG atezolizumab
- DRUG obrixtamig
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 670 participants |
| Start Date | 2026-04-13 |
| Est. Completion | 2029-07-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07472517
The ClinicalTrials.gov registry entry for NCT07472517 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 670 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which carboplatin is the first listed.
NCT07472517 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07472517 about?
NCT07472517 is a clinical study titled "DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy". This study is open to adults with advanced small cell lung cancer (SCLC). The purpose of this study is to find out if a study medicine called obrixtamig plus standard treatment (atezolizumab, carboplatin, and etoposide) improves survival when compared to standard treatment alone. Obrixtamig is an an...
What is the current status of trial NCT07472517?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 670 participants. The study started on 2026-04-13. Estimated completion is 2029-07-30.
What interventions are being tested in trial NCT07472517?
The interventions under investigation include: carboplatin (DRUG), etoposide (DRUG), atezolizumab (DRUG), obrixtamig (DRUG).
Who is sponsoring clinical trial NCT07472517?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.